Notice for sacituzumab govitecan (Adjutor Healthcare Pty Ltd)
Active ingredients
sacituzumab govitecan
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies
Therapeutic area
Oncology